Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370042 | 0.82 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5362620 | 0.82 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5370677 | 0.76 | ITGB1 (0.77) | ITGB1ITGA4 | |
| SCHEMBL5359109 | 0.72 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5367575 | 0.71 | ITGB1 (0.69) | ITGB1ITGA4 | |
| SCHEMBL5361757 | 0.71 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL6105278 | 0.70 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5361754 | 0.69 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL6518276 | 0.69 | ITGB1 (0.71) | ITGB1ITGA4 | |
| SCHEMBL5204869 | 0.68 | ITGB1 (0.50) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028812-A1 | Phenylalanine derivatives | CELLTECH CHIROSCIENCE LIMITED (GB) | 2002-03-07 | — | — | US | claimed |
| US-6348463-B1 | Phenylalanine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-02-19 | — | — | US | claimed |
| EP-1117657-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018759-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-06 | — | — | WO | claimed |
| US-6348463-B1 | Phenylalanine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-02-19 | — | — | US | disclosed |
| EP-1117657-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018759-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028812-A1 | Phenylalanine derivatives | PAH, FPR1, VCAM1 | ITGB1 4/4885ITGA4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.